American Diabetes Association

The FDA user fee reauthorization loosens conflict of interest rules for advisory committees, but may not actually result in a substantive change in agency practices. Its biggest impact may be to boost

Sanofi has dominated the insulin market since it introduced long-acting Lantus in 2000, capturing about 80% of the market share with $4.9 billion in sales in 2011. Novo Nordisk AS , a major pla

Although longtime leaders in diabetes therapies, Sanofi and Eli Lilly & Co. are both latecomers to the emerging battleground of glucagon-like peptide-1 agonists. With their compounds now in Phas

In an effort to finally bring a diabetes drug to market – one that could complement its medical device and diagnostics businesses – Johnson & Johnson has filed a new drug application with FDA for